KALA BIO, Inc. (KALA) Q2 2022 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Kala Bio, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.089 -- 00:00:04.011 Good day, my name is Chantal and I will be your conference operator today. 00:00:04.011 -- 00:00:08.142 At this time, I would like to welcome everyone to the Cali Pharmaceuticals second quarter 00:00:08.142 -- 00:00:13.315 2022 financial results conference call. As a reminder, today's conference call 00:00:13.315 -- 00:00:17.556 is being recorded. All lines have been placed on mute to prevent any background noise. 00:00:17.556 -- 00:00:20.938 After the speaker's remarks, there will be a question and answer session. 00:00:20.938 -- 00:00:24.419 If you would like to ask a question during this time, simply press star followed by the 00:00:24.419 -- 00:00:28.569 number one on your telephone keypad. If you'd like to withdraw your question, please 00:00:28.569 -- 00:00:33.510 press star one again. Thank you. Hannah Deresiewicz from Stern Investor Relations, you 00:00:33.510 -- 00:00:36.050 may begin your conference. 00:00:37.971 -- 00:00:42.932 Thank you, Operator, and thank you all for participating in today's call. 00:00:42.932 -- 00:00:48.033 Joining me from the company are Mark Iwiki, Chairman and Chief Executive Officer, 00:00:48.033 -- 00:00:53.334 Kim Brazel, Head of R&D and Chief Medical Officer, and Mary Remus, Chief 00:00:53.334 -- 00:00:58.432 Financial Officer. Darius Karabi, our Chief Business Officer, will also be 00:00:58.432 -- 00:01:02.055 joining us for the Q&A portion of today's call. 00:01:02.055 -- 00:01:07.000 During this call, we will be referring to non-GAAP financial measures, which are not 00:01:07.000 -- 00:01:11.303 prepared in accordance with generally accepted accounting principles. 00:01:11.303 -- 00:01:16.448 A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP 00:01:16....